We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$980M
AUM Growth
+$260M
Cap. Flow
+$88.5M
Cap. Flow %
9.03%
Top 10 Hldgs %
50.1%
Holding
93
New
25
Increased
16
Reduced
28
Closed
20
Avg Time Held Equity + Options
4.1 quarters
Top 10 Avg Time Held Equity + Options
1.1 quarters
Top 20 Avg Time Held Equity + Options
2.3 quarters
Avg Time Held Equity only
4.4 quarters
Top 10 Avg Time Held Equity only
1.1 quarters
Top 20 Avg Time Held Equity only
2.4 quarters

Top Buys

Rank Stock Value
1
ZBIO icon
Zenas BioPharma
ZBIO
+$25.5M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$18.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.5M
5
IMNM icon
Immunome
IMNM
+$16.1M

Top Sells

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$14.2M
2
CGON icon
CG Oncology
CGON
+$11M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
4
PFE icon
Pfizer
PFE
+$10.4M
5
AVTX icon
Avalo Therapeutics
AVTX
+$9.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Miscellaneous 13.39%
3 Financials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.03B
$105M 10.75%
+825,000
New +$225M
2026 Q1
0 quarters
KALV icon
2
DELISTED
KalVista Pharmaceuticals
KALV
$57.9M 5.91%
2,876,407
+449,289
+19% +$7.24M
2023 Q1
12 quarters
DNTH icon
3
Dianthus Therapeutics
DNTH
$4.36B
$54.9M 5.61%
654,746
-95,390
-13% -$5.52M
2025 Q1
4 quarters
COGT icon
4
Cogent Biosciences
COGT
$4.97B
$50.6M 5.16%
1,314,189
+68,935
+6% +$2.55M
2025 Q3
2 quarters
CELC icon
5
Celcuity
CELC
$3.01B
$40.9M 4.17%
357,903
-17,229
-5% -$1.88M
2025 Q3
2 quarters
IMNM icon
6
Immunome
IMNM
$2.09B
$40.5M 4.13%
1,850,278
+724,068
+64% +$16.1M
2025 Q4
1 quarter
KOD icon
7
Kodiak Sciences
KOD
$5.49B
$37.8M 3.86%
991,930
-31,192
-3% -$806K
2023 Q3
10 quarters
NUVL icon
8
DELISTED
Nuvalent
NUVL
$36.4M 3.71%
354,914
+43,484
+14% +$4.43M
2023 Q4
9 quarters
ABVX icon
9
Abivax
ABVX
$7.79B
$33.7M 3.44%
302,530
-119,663
-28% -$14.2M
2025 Q3
2 quarters
GLUE icon
10
Monte Rosa Therapeutics
GLUE
$845M
$32.9M 3.36%
2,002,040
+972,974
+95% +$18.6M
2025 Q3
2 quarters
ERAS icon
11
Erasca
ERAS
$5.21B
$30M 3.06%
1,851,812
+534,228
+41% +$6.31M
2024 Q1
8 quarters
ASND icon
12
Ascendis Pharma A/S
ASND
$14.9B
$28.5M 2.91%
124,658
+75,430
+153% +$16.9M
2024 Q3
6 quarters
URGN icon
13
UroGen Pharma
URGN
$1.88B
$27M 2.76%
1,503,045
-235,776
-14% -$4.73M
2023 Q3
10 quarters
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$6B
$26.6M 2.72%
306,000
+170,050
+125% +$16.5M
2023 Q2
11 quarters
PRAX icon
15
Praxis Precision Medicines
PRAX
$6.77B
$23.1M 2.35%
71,552
-10,913
-13% -$3.38M
2023 Q2
11 quarters
ZBIO icon
16
Zenas BioPharma
ZBIO
$1.64B
$22.2M 2.27%
+1,135,935
New +$25.5M
2026 Q1
0 quarters
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.24B
$20.8M 2.12%
888,987
+246,088
+38% +$5.35M
2024 Q2
7 quarters
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$18.5M 1.89%
466,345
+8,142
+2% +$208K
2024 Q3
6 quarters
SRRK icon
19
Scholar Rock
SRRK
$4.91B
$16.7M 1.7%
+339,613
New +$15.2M
2026 Q1
0 quarters
ALKS icon
20
Alkermes
ALKS
$6.74B
$16.3M 1.66%
+460,314
New +$14.3M
2026 Q1
0 quarters
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.21B
$13.9M 1.42%
1,100,010
-16,594
-1% -$188K
2022 Q2
15 quarters
IRON icon
22
Disc Medicine
IRON
$2.18B
$12.5M 1.28%
+196,028
New +$13.6M
2026 Q1
0 quarters
HLXC icon
23
Helix Acquisition Corp III
HLXC
$231M
$12.3M 1.25%
+1,208,986
New +$12.4M
2026 Q1
0 quarters
XENE icon
24
Xenon Pharmaceuticals
XENE
$3.35B
$11.5M 1.17%
+197,759
New +$9.11M
2026 Q1
0 quarters
CGON icon
25
CG Oncology
CGON
$5.53B
$11.3M 1.15%
166,349
-194,809
-54% -$11M
2025 Q2
3 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Silverarc Capital Management held 93 positions worth $980M, up 36% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $88.5M of net new capital in Q1 2026, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Zenas BioPharma: 1,135,935 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Abivax, an estimated $14.2M trimmed.

  • Silverarc Capital Management's largest Q1 2026 buy was Zenas BioPharma: 1,135,935 shares worth $22.2M.
  • Silverarc Capital Management added most to Monte Rosa Therapeutics in Q1 2026, an estimated $18.6M increase.
  • Silverarc Capital Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $14.2M.
  • Silverarc Capital Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $10.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $980M portfolio in Q1 2026.
  • Silverarc Capital Management opened 25 new positions and closed 20 in Q1 2026.
  • Silverarc Capital Management's portfolio value rose 36% quarter-over-quarter to $980M.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.